INS and type 1 diabetes mellitus: Alternative strategies have included the development of targeted immunomodulation such as oral insulin, DiaPep 277, GAD65, which have fewer side effects, but are probably more suitable for evaluation at an earlier stage of the life course of type 1 diabetes, to prevent progression from genetic susceptibility to the development of islet-related autoantibodies or from autoantibody positivity to the development of symptomatic type 1 diabetes [9, 10].